Dexcom (DXCM) Notes Payables (2022 - 2025)
Dexcom (DXCM) reported Notes Payables of $1.2 billion for Q3 2025, little changed on a QoQ basis from $1.2 billion in Q2 2025.
Dexcom (DXCM) has 4 years of Notes Payables data on file, last reported at $1.2 billion in Q3 2025.
- Quarterly Notes Payables changed N/A year-over-year to $1.2 billion in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.2 billion (changed N/A YoY) and the FY2024 annual result came in at $1.2 billion, changed N/A from the prior year.
- Notes Payables steadied at $1.2 billion in Q3 2025 per DXCM's latest filing, from $1.2 billion in the prior quarter.
- Across five years, Notes Payables topped out at $1.2 billion in Q3 2025 and bottomed at $124.2 million in Q3 2023.
- The 4-year median for Notes Payables is $989.1 million (2023), against an average of $908.3 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.21 Bn |
| Jun 30, 2025 | 1.21 Bn |
| Mar 31, 2025 | 1.21 Bn |
| Dec 31, 2024 | 1.20 Bn |
| Sep 30, 2023 | 124.20 Mn |
| Jun 30, 2023 | 773.80 Mn |
| Mar 31, 2023 | 773.20 Mn |
| Dec 31, 2022 | 772.60 Mn |